Comparisons of demographic, clinical and haemodynamic characteristics between patients with alcoholic hepatitis in the microarray cohort and validation cohort
| Microarray cohort (n=13) | Validation cohort (n=35) | ||
|---|---|---|---|
| Median (25–75 IQR) | Median (25–75 IQR) | p Value | |
| Characteristics | |||
| Age (years) | 54 (41–56) | 52 (45–55) | ns |
| Male, n (%) | 8 (62) | 27 (73) | ns |
| Alcohol intake (g/day) | 100 (90–100) | 100 (85–175) | ns |
| Corticosteroids, n (%) | 5 (39) | 18 (49) | ns |
| Cirrhosis (%) | 9 (69) | 30 (81) | ns |
| Laboratory and haemodynamic parameters | |||
| Haemoglobin (g/dL) | 11 (8–12) | 11 (10–13) | ns |
| Leucocyte count ×109/L | 8.7 (6.4–11.9) | 8.0 (5.8–12.2) | ns |
| Platelet count ×109/L | 90 (45–193) | 118 (76–197) | ns |
| AST (U/L) | 109 (61–193) | 125 (70–185) | ns |
| ALT (U/L) | 45 (32–78) | 44 (23–59) | ns |
| Serum Na (mmol/L) | 133 (129–136) | 135 (131–139) | ns |
| Serum albumin (g/dL) | 2.6 (2.4–2.9) | 2.7 (2.3–3.2) | ns |
| Serum creatinine (mg/dL) | 0.6 (0.6–1.0) | 0.8 (0.60–1.0) | ns |
| Serum bilirubin (mg/dL) | 11 (5–21) | 6 (2–20) | ns |
| INR | 1.6 (1.3–2.2) | 1.5 (1.3–1.7) | ns |
| HVPG (mm Hg) | 19 (15–25) | 19 (13–21) | ns |
| Alcoholic hepatitis severity scores at admission | |||
| MELD score | 22 (16–26) | 19 (13–24) | ns |
| ABIC score | 7.9 (6.3–8.8) | 7.3 (6.7–8.3) | ns |
| Clinical complications during hospitalisation | |||
| AKI*, n (%) | 3 (23) | 14 (38) | ns |
| Infection, n (%) | 7 (53) | 12 (32) | ns |
*Acute kidney injury was defined as an abrupt (within 48 h) reduction in kidney function currently defined as an absolute increase in serum creatinine of ≥0.3 mg/dL (≥26.4 μmol/L), a percentage increase in serum creatinine of ≥50% (1.5-fold from baseline) based on Acute Kidney Injury Network criteria.
ABIC, age-bilirubin-INR-creatinine score; AKI, acute kidney injury; ALT, alanine aminotransferase level; AST, aspartate aminotransferase level; HVPG, hepatic venous pressure gradient; INR, international normalised ratio; MELD, model for end-stage liver disease.